Management Buyout of Caraco Pharmaceutical Investigated by Tripp Levy PLLC on Behalf of Caraco Shareholders

Tripp Levy PLLC, a leading national securities law firm, announces an investigation into the proposed acquisition of Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD). Caraco announced that it received a proposal from Sun Pharmaceutical Industries Ltd. (“Sun”) and Sun Pharma Global, Inc. (“Sun Global”) to acquire the remaining shares of Caraco that they do not already own for $4.75 per share. Sun and Sun Global currently own approx. 75.8% of the Caraco’s outstanding shares.

The investigation concerns, among other things, whether the consideration to be paid to Caraco shareholders is grossly unfair, inadequate, and substantially below the fair or inherent value of Caraco. Indeed, analysts have projected the true inherent value of Caraco is at least $6 per share. The investigation further concerns whether Sun and Sun Global, as the controlling shareholders of the company, as well as the board of directors of Caraco may have breached their fiduciary duties by not acting in Caraco shareholders' best interests in connection with the sale process of Caraco.

If you own Caraco common stock and you wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Tripp LevyTripp Levy PLLC125 East 82nd Street9th FloorNew York, New YorkToll Free: 877-772-3975Email: [e-mail]

Tripp Levy PLLC is a national law firm that specializes in mergers & acquisitions, takeover litigation, shareholder rights, and corporate governance matters in state and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.